We thank Dr. Alfonso for his comments about our study (1). His observations provide an opportunity: 1) to analyze the implications of the procedural finding of balloon slippage in patients with in-stent restenosis (ISR) treated by conventional balloon angioplasty; 2) to report whether a specific subgroup of patients benefited from cutting balloon angioplasty; and 3) to discuss the possible benefit of lesion pre-dilation using the cutting balloon in patients with ISR treated with drug-eluting stenting.
Rate Control in Atrial Fibrillation
We read with great interest the substudy of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) investigators on the approaches to control rate in atrial fibrillation (AF) (1) . Recent studies show that rate control may be adopted as first-choice therapy in a variety of patients with AF (2,3). The optimal level of heart rate during AF is, however, still unknown.
In the AFFIRM study, in accordance with the guidelines (4), a strict rate-control approach was applied that includes a resting heart rate Յ80 beats/min and either a 6-min walk test heart rate Յ110 beats/min or a mean heart rate on a 24-h Holter recording Յ100 beats/min, in combination with a maximum heart rate Յ110% of predicted maximum heart rate. The present study shows that this (strict) rate-control approach can be successfully achieved in two-thirds of the patients and that, in line with previous data, beta-blockers are most effective to accomplish this goal (5) . Serious adverse effects were uncommon. However, to obtain adequate rate control, atrioventricular node ablation and pacemaker implantation was performed in 108 of the 2,027 patients (5.3%), and an additional 147 patients (7.3%) had a pacemaker implanted for symptomatic bradycardia. In comparison, in the RAte Control versus Electrical cardioversion (RACE) study, a more lenient rate-control approach was followed (resting heart rate Ͻ100 beats/min) (3). In that study, 46% of the patients were treated with a beta-blocker. Severe drug adverse effects were also rare (0.8%). In contrast to the AFFIRM study, however, a pacemaker was implanted in only 3 of the 256 patients (1.2%, all after atrioventricular node ablation).
Unfortunately, the AFFIRM investigators give no data on the influence of the level of rate control on mortality and morbidity. Therefore, it still, remains unknown whether strict rate control is associated with an improved prognosis. To answer the question of which approach to rate control is most effective we will start the RAte Control Efficacy in permanent atrial fibrillation study (RACE II).
The AFFIRM Study: Approaches to Control Rate in Atrial Fibrillation
The optimal heart rate for patients with atrial fibrillation (AF) remains unclear; current guidelines are primarily based on clinical experience (1) . Recent randomized studies suggest combining beta-blockers or calcium channel blockers with digoxin to achieve better rate control at rest and during exercise (2-4). However, I believe clarification of the "approach to control rate in AF" by the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) investigators (4) is justified.
A total of 2,027 patients were randomized to the rate control arm of the AFFIRM trial between 1995 and 1999. Of these, 248 crossed over to the rhythm-control group due to "uncontrolled symptoms" and 108 underwent AV nodal ablation due to failure of pharmacologic therapy. Rate-control data at rest are available in only 740 (36.5%) patients, which deteriorates further to 361 (17.8%) if data regarding heart-rate control during exercise are desired.
This relative lack of data may be explained by the fact that 1,055 (52%) patients were in sinus rhythm at the time of randomization. The proportion of those in the rate-control group who maintained sinus rhythm during follow-up is unclear. Published data for the entire trial population suggest a similar number (49%) remaining in sinus rhythm at study end.
Therefore, the majority of data on rate control of AF comes from a minority of patients randomized to a rate-control strategy. Because of the nature of data collection (only patients with AF at the time of assessment were selected for analysis), care should be taken in interpreting these results. The data predominantly represent patients with persistent and permanent AF and significantly underrepresent those with paroxysmal AF.
It is difficult to make conclusions on the control of ventricular rate during paroxysms of AF from this study, the occurrence of which greatly depends on variations of the autonomic tone (5).
